Overview

Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Northwestern University
Treatments:
upadacitinib